Recruiting Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis NCT07726147 Conditions Allergen Immunotherapy, Hypersensitivity, Hypersensitivity, Immediate, +8 more Locations Medical Corporation Shinanokai SHINANOZAKA Clinic — Tokyo, Shinjuku-ku, Japan View Trial Details
Not Yet Recruiting Allergy, Asthma, and Atopic Eczema in Finland NCT06330974 Conditions Allergen Immunotherapy, Allergy, Asthma, +22 more Locations Tampere University — Tampere, Finland View Trial Details
Completed Criteria Used by Health Professionals on the Selection of Allergen Immunotherapy in Real Clinical Practice NCT04038268 Conditions Allergen Immunotherapy, Respiration Disorders, Respiratory Tract Diseases Locations Uhmontpellier — Montpellier, France View Trial Details
